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Abstract: Background: Tranexamic acid is used to reduce bleeding, easy to use, affordable 
and relatively safe. There are few studies on the use of tranexamic acid in trauma and 
especially in neurosurgery. There is no published study on the trend the use of 
tranexamic acid in neurotrauma surgery among international doctors. The aim of this 
study was to evaluate the current practice for use of tranexamic acid during neurotrauma 
surgery. Materials and Methods: A 11-question electronic survey was sent to 25 
practicing physicians worldwide. Basic demographic information and estimated rates of 
use of tranexamic acid during neurotrauma surgery. Results: Twenty five physicians 
responded to our survey. Very Few trusts (12%) use tranexamic acid during 
neurotraumasurgery. Conclusion: Further studies are required to establish guidelines in 
neurosurgery and neurotrauma, especially. The use of this medicine potentially helps 
improve patient care with head injury and save lives. 
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Introduction 
Traumatic brain injury has been associated 
with significant mortality in the acute period. 
(1,2,3,4). There is great interest for the use of 
strategies that allow the decrease of bleeding 
within the surgical period. Very few trends 
studies have evaluated the use of tranexamic 
acid in surgery. (5,6). Until this date there is no 
study to assess the practical use of tranexamic 
acid in neuronal trauma surgery. The aim of 
this study was to record the use of tranexamic 
acid for neurotrauma surgery in physicians 
worldwide 
Materials and methods 
To determine how physicians 
internationally use tranexamic acid in brain 
trauma surgeries; we developed a web-based 
structured survey with real time results 
through an online survey 
(http://www.neuropractice.com). Survey 
invitations were sent by e-mail, and aimed 
physicians (Neurosurgeons, intensivist, 
residents of neurosurgery/critical care, trauma 
surgeons and others) who manage patients 
with brain traumatic injury, during the month 
of August of 2015 to September of 2015. For 
ethical considerations was decided not to 
identify any of the physician surveyed. We 
used dichotomous choice questions, and 
multiple choice questions with single answers. 
The evaluated variables were:  experience, 
occupation, place of training and use of 
ventriculostomy and placement of an 
intracranial pressure monitoring device. 
Answers from the survey were compiled and 
entered into an Excel database (Microsoft, 
Redmond, Washington). Each answer to a 
question was placed in a corresponding 
category and the frequencies of each category 
were computed. The data was analyzed by 
software 17.0 (SPSS. Inc., Chicago, IL). The 
data obtained was analyzed statistically and 
was determined the frequency distribution of 
each of the variables. 
Results 
Twenty five international physician 
completed the survey, all physician practiced 
in many countries. The time, of experienced 
was analyzed: 0-5 years (16%; n= 4), 5-10 years 
(20%; n=5), 10-20 years (36%; n=9), 21-
30(28%; n=7) years.  When asked about 
occupation the results were; neurosurgeon 
(32%; n=8), intensivist (36%; n=9), resident of 
neurosurgery/critical care (8%; n=2), trauma 
surgeon (8%; n=2), anesthesiologist (4%; n=1), 
RN critical care (4 %; n=1), others (8%; n=2). 
When asked about the use of tranexamic acid; 
yes (52%; n=13) and no (48%; n=12). When 
asked about the existence of an institutional 
policy for the use of tranexamic acid; yes (52%; 
n=13) and no (48%; n=12). When asked about 
the use tranexamic acid for all patients on 
neurotrauma surgery, (12%; n=3) and not 
(88%; n=22). When asked about the use of 
Tranexamic Acid in subdural chronic 
hematoma, yes (20%; n=5) and no (80%; 
n=20). When asked about the use Tranexamic 
Acid in recurrent subdural chronic hematoma; 
yes (12%; n=3) and no (88%; n=22). When 
asked about the   use Tranexamic Acid in 
Epidural hematoma; yes (36%; n=9) and no 
(64%; n=16). When asked about the use 
Tranexamic Acid in Acute subdural 
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hematoma; yes (44%; n=11) and no (56%; 
n=14). Regarding the discontinuation of 
maintenance (Tranexamic Acid) at the time of 
skin closure was performed; yes (16%; n=4) 
and no (84%; n=21). Other concern for the 
evaluation was the consideration of use with 
continuous infusion in the intensive care unit; 
yes (32%; n=8) and no (68%; n=17). 
Discussion 
Tranexamic acid is a synthetic derivative of 
the amino acid lysine that exerts its 
antifibrinolytic effect through the reversible 
blockade of lysine binding sites on 
plasminogen molecules. (6,7). The publication 
of the CRASH-2 trial opened a great interest in 
relation to the use of tranexamic acid and 
bleeding.  (9). This has motivated the interest 
on the role of fibrinolysis in bleeding. It has 
been shown that the effect of tranexamic acid 
is greater the day of injury; it also reduces the 
risk of death from all causes by 20%. It has 
been established that survival is only evident in 
patients treated initially in the first 3 hours.  
Until this day, no study has surveyed the use of 
tranexamic acid in patients with neuronal 
trauma. From this survey we can infer that 
52% of respondents’ trusts routinely use 
tranexamic acid in neurosurgery. Our results 
show an institutional policy for the use of 
tranexamic acid in 52%. There is disparity in 
the use of tranexamic acid; low use in neuronal 
trauma surgery in these cases may be 
beneficial. It is possible that some concerns 
about the possible complications derived from 
this drug are the reason of the low use of 
tranexamic acid. These complications have 
been estimated as too low. (10,11,12) Despite 
evidence showing this drug is much useful and 
has low risk of side effects, it is clear that its use 
is not part of routine practice in many of the 
same neurosurgical centers. 
Conclusion 
This survey shows on the current practice 
of physicians who specialize in neurotrauma 
surgery and tranexamic acid. As a relevant 
conclusion, further studies are required to 
achieve to provide a definitive dosing 
recommendations. Also, to confirm the role of 
tranexamic acid in the management of 
neurotrauma surgery and so the improvement 
of patient care. 
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